JP2022547541A5 - - Google Patents
Info
- Publication number
- JP2022547541A5 JP2022547541A5 JP2022515692A JP2022515692A JP2022547541A5 JP 2022547541 A5 JP2022547541 A5 JP 2022547541A5 JP 2022515692 A JP2022515692 A JP 2022515692A JP 2022515692 A JP2022515692 A JP 2022515692A JP 2022547541 A5 JP2022547541 A5 JP 2022547541A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- eye
- raav particles
- unit dose
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077233A JP2025118798A (ja) | 2019-09-11 | 2025-05-07 | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899070P | 2019-09-11 | 2019-09-11 | |
| US62/899,070 | 2019-09-11 | ||
| US201962913648P | 2019-10-10 | 2019-10-10 | |
| US62/913,648 | 2019-10-10 | ||
| PCT/US2019/062066 WO2021050094A1 (en) | 2019-09-11 | 2019-11-18 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| USPCT/US2019/062066 | 2019-11-18 | ||
| US202062959784P | 2020-01-10 | 2020-01-10 | |
| US62/959,784 | 2020-01-10 | ||
| US202062971835P | 2020-02-07 | 2020-02-07 | |
| US62/971,835 | 2020-02-07 | ||
| US202063019190P | 2020-05-01 | 2020-05-01 | |
| US63/019,190 | 2020-05-01 | ||
| US202063030819P | 2020-05-27 | 2020-05-27 | |
| US63/030,819 | 2020-05-27 | ||
| US202063063203P | 2020-08-07 | 2020-08-07 | |
| US63/063,203 | 2020-08-07 | ||
| PCT/US2020/050079 WO2021050649A1 (en) | 2019-09-11 | 2020-09-10 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077233A Division JP2025118798A (ja) | 2019-09-11 | 2025-05-07 | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547541A JP2022547541A (ja) | 2022-11-14 |
| JP2022547541A5 true JP2022547541A5 (enExample) | 2023-08-24 |
Family
ID=72644941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515692A Withdrawn JP2022547541A (ja) | 2019-09-11 | 2020-09-10 | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
| JP2025077233A Pending JP2025118798A (ja) | 2019-09-11 | 2025-05-07 | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077233A Pending JP2025118798A (ja) | 2019-09-11 | 2025-05-07 | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP4696318A1 (enExample) |
| JP (2) | JP2022547541A (enExample) |
| KR (1) | KR20220062353A (enExample) |
| CN (1) | CN114375195A (enExample) |
| AU (1) | AU2020345915A1 (enExample) |
| BR (1) | BR112022004027A2 (enExample) |
| CA (1) | CA3148376A1 (enExample) |
| DK (1) | DK4027983T3 (enExample) |
| ES (1) | ES3063491T3 (enExample) |
| FI (1) | FI4027983T3 (enExample) |
| HR (1) | HRP20260137T1 (enExample) |
| IL (1) | IL291182A (enExample) |
| LT (1) | LT4027983T (enExample) |
| MX (1) | MX2022002961A (enExample) |
| PT (1) | PT4027983T (enExample) |
| RS (1) | RS67774B1 (enExample) |
| SM (1) | SMT202600070T1 (enExample) |
| WO (1) | WO2021050649A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| JP7842082B2 (ja) * | 2020-07-21 | 2026-04-07 | エフティージェン コーポレーション | 眼疾患を処置するための組成物および方法 |
| BR112023019056A2 (pt) | 2021-04-27 | 2024-01-16 | Adverum Biotechnologies Inc | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte |
| US20240252679A1 (en) * | 2021-05-28 | 2024-08-01 | Shanghai Regenelead Therapies Co., Ltd. | Recombinant adeno-associated virus having variant capsid, and application thereof |
| WO2023028457A1 (en) * | 2021-08-23 | 2023-03-02 | Duke University | Compositions for and methods of long-term integration of circuits using connexins |
| WO2023158990A1 (en) * | 2022-02-16 | 2023-08-24 | Adverum Biotechnologies, Inc. | Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121772934A (zh) | 2023-08-01 | 2026-03-31 | 北京因诺惟康医药科技有限公司 | 融合多肽、包含其编码基因的表达盒、基因递送载体、药物组合物及用途 |
| KR20260004635A (ko) * | 2024-07-01 | 2026-01-09 | 삼성바이오에피스 주식회사 | 애플리버셉트를 암호화하는 코돈-최적화된 폴리뉴클레오티드를 포함하는 발현 카세트 및 이를 포함하는 rAAV 생산용 플라스미드 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2544136B2 (ja) * | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤 |
| TW201105363A (en) * | 2009-07-14 | 2011-02-16 | Univ Yamagata | Eye drop for macular edema treatment |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| GB2516138C (en) * | 2013-04-09 | 2015-12-09 | Cresset Biomolecular Discovery Ltd | The treatment of inflammatory disorders |
| ES2840059T3 (es) * | 2016-06-16 | 2021-07-06 | Adverum Biotechnologies Inc | Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
-
2020
- 2020-09-10 HR HRP20260137TT patent/HRP20260137T1/hr unknown
- 2020-09-10 RS RS20260196A patent/RS67774B1/sr unknown
- 2020-09-10 KR KR1020227011745A patent/KR20220062353A/ko active Pending
- 2020-09-10 CA CA3148376A patent/CA3148376A1/en active Pending
- 2020-09-10 EP EP25180005.8A patent/EP4696318A1/en active Pending
- 2020-09-10 DK DK20780467.5T patent/DK4027983T3/da active
- 2020-09-10 EP EP20780467.5A patent/EP4027983B1/en active Active
- 2020-09-10 MX MX2022002961A patent/MX2022002961A/es unknown
- 2020-09-10 BR BR112022004027A patent/BR112022004027A2/pt unknown
- 2020-09-10 WO PCT/US2020/050079 patent/WO2021050649A1/en not_active Ceased
- 2020-09-10 SM SM20260070T patent/SMT202600070T1/it unknown
- 2020-09-10 AU AU2020345915A patent/AU2020345915A1/en active Pending
- 2020-09-10 JP JP2022515692A patent/JP2022547541A/ja not_active Withdrawn
- 2020-09-10 LT LTEPPCT/US2020/050079T patent/LT4027983T/lt unknown
- 2020-09-10 PT PT207804675T patent/PT4027983T/pt unknown
- 2020-09-10 FI FIEP20780467.5T patent/FI4027983T3/fi active
- 2020-09-10 ES ES20780467T patent/ES3063491T3/es active Active
- 2020-09-10 CN CN202080063266.4A patent/CN114375195A/zh active Pending
-
2022
- 2022-03-08 IL IL291182A patent/IL291182A/en unknown
-
2025
- 2025-05-07 JP JP2025077233A patent/JP2025118798A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547541A5 (enExample) | ||
| JP2025506383A5 (enExample) | ||
| JP2024515459A5 (enExample) | ||
| FI4027983T3 (fi) | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla | |
| JP2021503914A5 (enExample) | ||
| JP2022141856A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2022522776A5 (enExample) | ||
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| JP2020526514A5 (enExample) | ||
| JP2015523060A5 (enExample) | ||
| JP2020537637A5 (enExample) | ||
| JP2025506681A5 (enExample) | ||
| JP2021511030A5 (enExample) | ||
| US20250137011A1 (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
| JP2022545967A5 (enExample) | ||
| JP2023545229A5 (enExample) | ||
| US20230175015A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| WO2021050094A1 (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
| JP2025509568A5 (enExample) | ||
| AU2023221321A1 (en) | Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus | |
| JP2022533983A5 (enExample) | ||
| JP2024148177A (ja) | アフリベルセプトをコードするａａｖ２バリアントを使用する眼内血管新生疾患を処置する方法 | |
| JP2022523050A5 (enExample) | ||
| JP2023531289A (ja) | 眼病態の処置のためのｄｎａ構造 |